CO-AEM
AEM today announced the highly anticipated update of the Earth Networks Total Lightning Network® (ENTLN). With significant enhancements to both location accuracy and lightning detection efficiency, the ENTLN now improves the ability for AEM customers to track real-time lightning and provide early warning for severe weather events that could threaten public safety and operational effectiveness.
The enhancements are driven through redesigns of the proprietary ENTLN algorithms and include:
- Exceptional lightning location accuracy now under 100 meters. With enhanced accuracy, those in charge of keeping people and assets safe from severe weather have further precision to make confident decisions in moments that matter.
- Detection efficiency over 95% regionally, with 30-50% more lightning detected worldwide. With increased detection efficiency, the ENTLN improves upon its industry leading reliability.
- 90% cloud-to-ground and in-cloud lightning classification accuracy . For customers who make decisions based on the type of lightning, improved classification enhances the ability to track lightning events relevant to a specific situation.
Lightning data from ENTLN is now available in expanded data formats for seamless consumption into 3rd party applications to investigate weather events, verify strikes and analyze lightning induced damage. These new network capabilities are also accompanied by a redesigned lightning sensor allowing for easier deployments and maintenance in remote environments.
The new lightning offering is now integrated into AEM’s suite of decision support applications including:
- Earth Networks Sferic Products – for safeguarding lives and assets from severe weather including lightning, high winds, and heavy precipitation, the Sferic product line provides over 120 map layers displaying current conditions and forecasting and enables custom alerts to be delivered via email, text, or via push notifications to a companion mobile app.
- OneRain Contrail® – for flood risk management and warning, dam safety, and reservoir gate operations, Contrail delivers lightning information to ensure first responder safety and identify more vigorous convective storms that may exacerbate local flash flooding and high-water conditions.
- FTS360 – for wildfire monitoring and mitigation, FTS360 integrates sensor and station data, camera imagery, and video to provide complete situational awareness of current and potential wildfire events. The lightning data improves response time by providing early detection and verification of potential wildfire ignitions.
“With environmental risks escalating and increased impacts from severe weather events around the world, both the public and private sectors are growing increasingly dependent on real-time weather insights to drive their emergency action plans, keep people safe, and minimize downtime,” said Mark Miller, Chief Commercial Officer, AEM. “We are excited to bring these improvements to our industry-leading lightning detection network and ensure decision makers have access to the most trusted and reliable lightning data on the market.”
“As an early adopter of the new ENTLN, we have been impressed with the increased detection efficiency and location accuracy it has brought to the Australia Total Lightning Network (ATLN),” said Martin Palmer, Managing Director, WeatherZone. “Their data, along with our solutions and insights, provides our customers with the operational intelligence they need to make agile and confident decisions. Earth Networks enables us to provide a comprehensive solution to organisations and businesses across Australia.”
Operating over 1,800 sensors across 100 countries, the Earth Networks Total Lightning Network is the most advanced global lightning network in the world. Its ability to comprehensively monitor both in-cloud and cloud-to-ground lightning enables the creation of faster severe weather alerts, lightning-derived radar alternatives and real-time storm visualization.
The new lightning network capabilities, as well as AEM’s broader set of environmental risk solutions, are on display at the American Meteorological Society (AMS) 102nd Annual Meeting from now until January 27, 2022. To learn more visit AEM at https://aem.eco .
About AEM
AEM is combining global technology leaders to empower communities and organizations to survive and thrive in the face of escalating environment risks. By deploying intelligent sensing networks, operating a secure and scalable data management infrastructure, and delivering high-value analytics through a suite of end-user applications, AEM serves as the essential source for environmental insights. These technologies enable positive outcomes, helping reduce environmental impact and creating a safer world. For more information, visit https://aem.eco .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005052/en/
Link:
Social Media:
https://www.facebook.com/Advanced-Environmental-Monitoring-AEM-110375228108391
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom